Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

Abstract Background In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. Our study explored the potential of enhancing ccRCC treatment by concurrently using CXCR2 i...

Full description

Bibliographic Details
Main Authors: Christopher Montemagno, Arnaud Jacquel, Charlotte Pandiani, Olivia Rastoin, Rosie Dawaliby, Thomas Schmitt, Maxence Bourgoin, Héliciane Palenzuela, Anne-Laure Rossi, Damien Ambrosetti, Jerome Durivault, Frederic Luciano, Delphine Borchiellini, Julie Le Du, Leticia Christina Pires Gonçalves, Patrick Auberger, Rachid Benhida, Lisa Kinget, Benoit Beuselinck, Cyril Ronco, Gilles Pagès, Maeva Dufies
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Renal Cell Carcinoma
M2 tumor associated macrophages
Immunotherapies resistance
CXCR2 inhibitors
Nivolumab
Ipilimumab
Online Access:https://doi.org/10.1186/s13046-024-02984-2

Internet

https://doi.org/10.1186/s13046-024-02984-2

Similar Items